Lexicon Pharma (LXRX) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.48 --0%
Revenue Growth %: -79.9%
Financial Fact:
Total revenues: 27.72M
Today's EPS Names:
RBKB, ASBH, CMSG, More
Revenue Growth %: -79.9%
Financial Fact:
Total revenues: 27.72M
Today's EPS Names:
RBKB, ASBH, CMSG, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.20), $0.02 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $1.25 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- Mohawk Industries (MHK) Tops Q3 EPS by 14c; offers guidance
- Starz Entertainment Corp. (STRZ) Reports Q3 Loss of $2.02
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
